Production (Stage)
China Pharma Holdings, Inc.
CPHI
$1.90
$0.0633.42%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -33.10% | -35.41% | -28.76% | -21.36% | -24.11% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -33.10% | -35.41% | -28.76% | -21.36% | -24.11% |
| Cost of Revenue | -14.55% | -10.67% | -6.21% | -1.79% | -16.70% |
| Gross Profit | -144.52% | -606.12% | -1,095.35% | -2,431.77% | -410.98% |
| SG&A Expenses | 1.97% | 3.97% | -8.73% | -11.49% | -16.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.95% | -6.61% | -3.77% | -1.90% | -15.69% |
| Operating Income | -35.50% | -66.76% | -67.28% | -55.10% | -7.76% |
| Income Before Tax | -28.31% | -53.84% | -52.50% | -40.97% | -4.07% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -28.31% | -53.84% | -52.50% | -40.97% | -4.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.31% | -53.84% | -52.50% | -40.97% | -4.07% |
| EBIT | -35.50% | -66.76% | -67.28% | -55.10% | -7.76% |
| EBITDA | -379.13% | -109,594.44% | -15,182.14% | -4,002.12% | -25.82% |
| EPS Basic | 73.94% | 74.88% | 79.46% | 74.18% | 70.30% |
| Normalized Basic EPS | 73.94% | 74.88% | 79.46% | 74.18% | 70.30% |
| EPS Diluted | 73.94% | 74.88% | 79.46% | 74.18% | 70.30% |
| Normalized Diluted EPS | 73.94% | 74.88% | 79.46% | 74.18% | 70.30% |
| Average Basic Shares Outstanding | 257.29% | 427.87% | 646.86% | 603.95% | 411.80% |
| Average Diluted Shares Outstanding | 257.29% | 427.87% | 646.86% | 603.95% | 411.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |